The Advanced Research Projects Agency for Health (ARPA-H) has appointed American College of Radiology (ACR) Chief Research Officer (CRO) Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical trial portfolio and lead the ARPA-H Advancing Clinical Trials Readiness Initiative under ARPA-H Resilient Systems Mission Office Director Jennifer Roberts. Image courtesy: NIH
March 21, 2024 — The Advanced Research Projects Agency for Health (ARPA-H) has appointed American College of Radiology (ACR) Chief Research Officer (CRO) Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical trial portfolio and lead the ARPA-H Advancing Clinical Trials Readiness Initiative under ARPA-H Resilient Systems Mission Office Director Jennifer Roberts.
The first radiologist to be appointed to such a role, Pisano is an internationally-recognized expert in women’s health, breast cancer research and artificial intelligence (AI) in medical imaging applications, according to an ACR news announcement.
"I am honored to be working for ARPA-H to identify and promote research that can improve healthcare quality, efficacy and delivery, and to improve patient care and access to clinical trials for all Americans, including women, rural residents and the underserved,” said Pisano.
The Advanced Research Projects Agency for Health (ARPA-H), an independent entity within the National Institutes of Health (NIH) defines itself in the following manner: ARPA-H is a research funding agency that supports transformative biomedical and health breakthroughs – ranging from the molecular to the societal – to provide health solutions for all. ARPA-H makes pivotal investments in breakthrough technologies and broadly applicable platforms, capabilities, resources, and solutions with the potential to transform important areas of medicine and health that cannot readily be accomplished through traditional research or commercial activity.
Pisano will continue to serve as ACR CRO and as study chair of the large-scale Tomosynthesis Mammographic Imaging Screening Trial (TMIST), according to the announcement. The ACR statement added that she also remains an adjunct professor of radiology at the University of Pennsylvania Perelman School of Medicine. Pisano previously served as principal investigator of the landmark Digital Mammographic Imaging Screening Trial (DMIST ).
TMIST is among the fastest growing National Cancer Institute (NCI) trials of the COVID-19 era. Under study chair Pisano, TMIST is assembling one of the most diverse cancer screening trial populations ever. Approximately 21% of TMIST U.S. participants are Black — more than double the average rate for Black participation in NCI-funded clinical trials (9%). TMIST is led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) with funding from the NCI, part of the National Institutes of Health.
With ARPA-H, Pisano will work to build underserved and minority participation in clinical trials — including identifying and onboarding rural facilities and those outside of large academic medical centers — such as emerging retail healthcare sites.
These duties, noted ACR, are also very compatible with the missions of the ACR, the ACR Center for Research and Innovation and the ACR Data Science Institute, which include promoting exploration and identification of next-generation technologies that can benefit patients and providers.
More information: www.acr.org
May 08, 2024 
